Background {#Sec1}
==========

Diabetic retinopathy is a major vascular complication of diabetes mellitus (DM), often leading to low vision and blindness \[[@CR1], [@CR2]\]. It can become a major threat to public health in the future due to the increasing global prevalence of DM, which is projected to affect 438 million people by 2030 \[[@CR3]\]. Diabetic retinopathy occurs in 70% of patients with diabetes for more than 15 years. A recent study indicated that the estimated prevalence of diabetic retinopathy was 28.5% among US adults \[[@CR4]\]. The pathogenesis and etiology of diabetic retinopathy include poor glycemic control, vascular endothelial cell injury, hypercoagulability, ischemia and anoxia of retina, and genetic factors \[[@CR5]\].

Homocysteine (Hcy) is a sulfur-containing amino acid formed by the demethylation of methionine. Plasma Hcy level is elevated in patients with diabetes, particularly those with type 2 diabetes as well as in pre-diabetic individuals with insulin resistance \[[@CR6]\]. It is an emerging risk factor for diabetic retinopathy and cardiovascular disease that has become a research hotspot \[[@CR7]\]. B vitamin is an essential vitamin for humans and an important cofactor of Hcy metabolism, which is commonly related to high circulating levels of Hcy. The effect of B vitamin supplementation on the progression of diabetic retinopathy in diabetic patients remains unknown, and requires a systematic review and meta-analysis.

A few studies have suggested that the level of plasma and vitreous Hcy is a risk factor for diabetic retinopathy \[[@CR8]--[@CR10]\], while others have refuted this link \[[@CR11], [@CR12]\]. Therefore, the present meta-analysis was performed to summarize currently available data to provide more robust evidence on the potential relationship between Hcy level and the risk of diabetic retinopathy.

Methods {#Sec2}
=======

Data sources, search strategy, and selection criteria {#Sec3}
-----------------------------------------------------

This meta-analysis was conducted according to the preferred reporting items for systematic reviews and meta-analysis guidelines \[[@CR13]\]. All studies written in English that investigated the relationship between plasma Hcy level and diabetic retinopathy in diabetic patients were considered for this meta-analysis, regardless of the publication status (published, in press, or in progress). The PubMed, Embase, and Cochrane Library databases were independently searched by two authors to retrieve related original studies published before November 2017. The search terms used were as follows: "diabetic retinopathy," "diabetic retinopathies," "homocysteine," and "Hcy". Furthermore, the reference lists of all eligible studies were manually searched to identify any additional relevant studies.

The study selection was independently performed by two authors with a standardized approach, and any inconsistencies were resolved by group discussion and consensus. Studies that met the following inclusion criteria were included in this meta-analysis: (1) the study had an observational design; (2) the study reported the association of Hcy level with the risk of diabetic retinopathy; and (3) the study reported the sample size, diabetic retinopathy incidence or effect estimate. Studies that met any one of the following conditions were excluded: (1) article type: editorials, meta-analysis, and review articles; (2) did not report diabetic retinopathy (including proliferative and nonproliferative); and (3) duplication of published articles.

Data collection and quality assessment {#Sec4}
--------------------------------------

Data were independently extracted from each included study by two authors, and all disagreements were discussed and resolved with the help of the third author. The following information was recorded: first author's name, publication year, country, sample size, mean age, percentage male, body mass index (BMI), diabetes mellitus types, cutoff value of Hcy, adjusted factors, and reported outcomes. The quality of selected studies was evaluated using the Newcastle--Ottawa Quality Assessment Scale (NOS) \[[@CR14]\]. The maximal NOS score was 9 points, and studies ≥ 7 points were considered to be of relatively higher quality. The quality assessment was independently conducted by two authors, and information was examined and adjudicated by an additional author after referring to the original studies.

Statistical analysis {#Sec5}
--------------------

Odds ratios and 95% confidence intervals (CIs) was used to assess the relationship between Hcy level and the risk of diabetic retinopathy in diabetic patients. The random-effects model was used to calculate summary ORs and 95% CIs for the high versus low Hcy levels \[[@CR15], [@CR16]\]. Heterogeneity among the included studies was quantified using the *I*-square (*I*^2^) value. *I*^2^\> 50% was considered to represent significant heterogeneity \[[@CR17]\]. We also performed a sensitivity analysis by removing each individual study from the meta-analysis \[[@CR18]\]. Univariate meta-regression analysis based on sample size, mean age, percentage male, and BMI was used to explore the source of heterogeneity in estimates of the risk on diabetic retinopathy \[[@CR19]\]. Subgroup analysis was conducted for diabetic retinopathy according to publication year, country, sample size, mean age, percentage male, BMI, diabetes mellitus types, and NOS score. Furthermore, ratio between subgroups was calculated to compare the differences between estimates of the two subsets, which were based on Student *t* distribution rather than normal distribution because of the small number of included studies \[[@CR20]\]. Funnel plot, Egger and Begg tests were performed to evaluate the potential publication bias \[[@CR21], [@CR22]\]. All reported p values are two-sided, and p \< 0.05 was regarded as statistically significant. All analyses were performed using STATA software package (version 10.0; Stata Corp, TX, USA).

Results {#Sec6}
=======

Initially 249 studies were extracted from PubMed, Embase, and the Cochrane Library databases, of which 211 studies were excluded after reviewing the titles and abstracts because they were unrelated to the topic or duplicates. By examining the full texts of the remaining 38 articles, 27 were excluded for including the same group of patients, reporting other outcomes, or without available data. A manual search of the reference lists of these studies did not yield any new eligible studies. The results of the study-selection process are shown in Fig. [1](#Fig1){ref-type="fig"}. Finally, 11 studies involving 2184 diabetic patients were included in this meta-analysis \[[@CR3], [@CR23]--[@CR32]\].Fig. 1Flow diagram of the literature search and trial selection process

The characteristics of the 11 included studies are shown in Table [1](#Tab1){ref-type="table"}. The included studies were published between 1997 and 2014, and 25--625 diabetic patients were included in each study. Four of the included studies were conducted in Eastern countries \[[@CR23], [@CR28], [@CR30], [@CR31]\], and the remaining seven studies were conducted in Western countries \[[@CR3], [@CR23]--[@CR27], [@CR29], [@CR32]\]. Furthermore, four studies included patients with type 1 diabetes mellitus \[[@CR23], [@CR24], [@CR26], [@CR32]\], five studies included patients with type 2 diabetes mellitus \[[@CR3], [@CR25], [@CR29]--[@CR31]\], and the remaining two studies included both type 1 and 2 diabetes mellitus \[[@CR27], [@CR28]\]. The mean age of patients in individual studies ranged from 43.8 to 69.4 years, the percentage male ranged from 41.9 to 78.6%, and mean BMI ranged from 24.2 to 29.6 kg/m^2^. NOS was used to evaluate the quality of each study, whereby two of the included studies had a score of 8 \[[@CR24], [@CR30]\], five studies had a score of 7 \[[@CR3], [@CR25], [@CR26], [@CR28], [@CR32]\], and the remaining four studies had a score of 6 \[[@CR23], [@CR27], [@CR29], [@CR31]\].Table 1Baseline characteristics of studies included in the systematic review and meta-analysisStudyPublication yearCountrySample sizeMean age (years)Percentage male (%)BMI (kg/m^2^)DM typesCutoff of Hcy (μmol/L)Adjusted factorNOS scoreVaccaro \[[@CR23]\]1997Japan2544.972.0NA110.0Age, gender, blood pressure, creatinine, plasma cholesterol, smoking status6Hofmann \[[@CR24]\]1998France7551.046.724.2115.8Age, gender, diabetes duration, diabetes control, blood pressure, BMI, plasma cholesterol8Hoogeveen \[[@CR25]\]2000Netherlands62564.348.227.2216.0Age, gender, BMI, creatinine, plasma cholesterol7Buysschaert \[[@CR26]\]2000Belgium12262.667.229.6115.0Age, gender, diabetes duration, hypoglycemia medication, blood pressure, triglyceride, LDL, HDL7Agullo-Ortuno \[[@CR27]\]2002Spain8943.851.7NABoth15.6 (men) and 13.9 (women)Plasma cholesterol, triglyceride, LDL, HDL6Goldstein \[[@CR28]\]2004Israel33569.451.3NABoth15.0Age, blood pressure, other complications7de Luis \[[@CR29]\]2005Spain15564.641.929.6215.0Age, blood pressure, BMI, creatinine, plasma cholesterol6Golbahar \[[@CR30]\]2008Bahrain25456.154.325.5212.0 (men) and 15.0 (women)Age, gender, diabetes duration, diabetes control, BMI, HDL, smoking status8Satyanarayana \[[@CR3]\]2011US30055.156.124.4212.0Age, hypoglycemia medication, plasma cholesterol, low density lipoprotein7Sato \[[@CR31]\]2013Japan8462.078.625.3210.0Metformin, eGFR, and B126Bulum \[[@CR32]\]2014Croatia10047.054.025.0115.0Age, eGFR, blood pressure, triglyceride7*LDL* low-density lipoprotein, *HDL* high-density lipoprotein, *BMI* body mass index

All included studies reported an association between Hcy and diabetic retinopathy. Pooled analysis results indicated that elevated Hcy level was associated with an increased risk of diabetic retinopathy (OR 1.62; 95% CI 1.29--2.03; p \< 0.001; Fig. [2](#Fig2){ref-type="fig"}). Although substantial heterogeneity was observed in the magnitude of the effect across the studies (I^2^ = 58.1%; p = 0.008), the conclusion was not affected after sequential exclusion of any specific study from the pooled analyses (Table [2](#Tab2){ref-type="table"}).Fig. 2Association between homocysteine level and the risk of diabetic retinopathy Table 2Sensitivity analysis for diabetic retinopathy riskExcluding studyOR and 95% CIp valueHeterogeneity (%)p value for heterogeneityVaccaro1.57 (1.26--1.96)\< 0.00156.70.014Hofmann1.64 (1.29--2.09)\< 0.00162.30.005Hoogeveen1.64 (1.28--2.11)\< 0.00162.30.005Buysschaert1.66 (1.31--2.12)\< 0.00161.90.005Agullo-Ortuno1.58 (1.26--1.99)\< 0.00159.60.008Goldstein1.50 (1.21--1.85)\< 0.00147.20.048de Luis1.66 (1.31--2.11)\< 0.00161.60.005Golbahar1.49 (1.21--1.84)\< 0.00146.90.049Satyanarayana1.58 (1.24--2.02)\< 0.00158.40.010Sato1.74 (1.30--2.34)\< 0.00160.00.007Bulum1.75 (1.32--2.32)\< 0.00154.50.019*OR* odds ratio, *CI* confidence interval

Heterogeneity testing showed a value of p \< 0.10 for diabetic retinopathy. Therefore, a meta-regression analysis was conducted based on sample size, mean age, percentage male, and BMI. Overall, sample size (p = 0.412), mean age (p = 0.892), percentage male (p = 0.659), and BMI (p = 0.452) did not significantly affect the relationship between Hcy and diabetic retinopathy (Additional file [1](#MOESM1){ref-type="media"}). The results of subgroup analysis indicated that this relationship in most subsets was consistent with the overall analysis (Table [3](#Tab3){ref-type="table"}). However, elevated Hcy level was not associated with the risk of diabetic retinopathy if the sample size was \< 100, the study included patients with type 1 diabetes mellitus, and the study was low quality.Table 3Subgroup analysis for diabetic retinopathy riskGroupOR and 95% CI*p* valueHeterogeneity (%)*p* value for heterogeneityRatio between subgroupsPublication year Before 20051.89 (1.26--2.81)0.00231.00.2031.29 (0.80--2.07)/0.300 2005 or after1.47 (1.14--1.90)0.00366.20.019Country Eastern2.26 (1.24--4.13)0.00881.40.0011.73 (0.93--3.21)/0.085 Western1.31 (1.12--1.52)0.0011.30.415Sample size ≥ 1001.66 (1.21--2.29)0.00266.90.0060.99 (0.52--1.88)/0.971 \< 1001.68 (0.96--2.92)0.06742.90.154Mean age (years) ≥ 60.01.47 (1.05--2.05)0.02550.60.0880.77 (0.45--1.32)/0.350 \< 60.01.90 (1.25--2.90)0.00368.20.008Percentage male (%) ≥ 55.01.51 (1.04--2.21)0.03252.30.0990.87 (0.52--1.48)/0.612 \< 55.01.73 (1.20--2.50)0.00365.70.008BMI (kg/m^2^) ≥ 25.01.35 (1.10--1.67)0.00445.10.1050.75 (0.48--1.17)/0.211 \< 25.01.79 (1.21--2.64)0.0040.00.488DM types 11.27 (0.93--1.75)0.13417.30.3050.79 (0.50--1.24)/0.306^a^ 21.61 (1.16--2.23)0.00559.70.042 Both2.71 (1.70--4.30)\< 0.0010.00.917Study quality High1.70 (1.24--2.33)0.00166.00.0071.06 (0.56--2.03)/0.854 Low1.60 (0.91--2.82)0.10645.90.136*OR* odds ratio, *CI* confidence interval, *BMI* body mass index, *DM* diabetes mellitus^a^Compared between type 1 and 2 DM

The funnel plots did not rule out publication bias for diabetic retinopathy (Fig. [3](#Fig3){ref-type="fig"}). Although the Begg test showed no evidence of publication bias for diabetic retinopathy (p = 0.350), the Egger test showed potential evidence of publication bias for diabetic retinopathy (p = 0.051). The conclusions were not changed after adjustment for publication bias using the trim and fill method (OR 1.55; 95% CI 1.24--1.94; p \< 0.001) \[[@CR33]\].Fig. 3Funnel plot for diabetic retinopathy

Discussion {#Sec7}
==========

Although many studies have indicated an association between Hcy and diabetic retinopathy, the results are conflicting \[[@CR34], [@CR35]\]. Among the many determinants of Hcy, the B-vitamin status was shown to be a major regulating factor; however, its relationship with diabetic retinopathy remains unclear \[[@CR3]\]. This meta-analysis summarized 11 studies involving a total of 2184 diabetic patients from nine countries and regions in three continents. Elevated Hcy level was associated with an increased risk of diabetic retinopathy in diabetic patients. We are confident in this result, which was persistent after excluding any specific study. However, subgroup analysis indicated no significant difference between Hcy and diabetic retinopathy in studies with sample size \< 100, participants with type 1 diabetes mellitus, and low quality.

Diabetic retinopathy is one of the most severe microvascular complications, which occurs due to metabolic disorders and endocrine system damage in diabetic patients \[[@CR36]\]. The complex pathogenesis includes nonproliferative retinopathy (capillary swelling and deformation, blood-retinal barrier damage and retinal leakage, macular edema, and vision damage), followed by proliferative retinopathy (neovascularization, vitreous hemorrhage, retinal detachment, and eventually blindness) \[[@CR37], [@CR38]\]. Recently, the effects of oxidative stress and inflammation on the role of diabetic retinopathy have been extensively studied. Hcy is involved in oxidation--reduction reaction and induces oxidative stress. Plasma Hcy level is regulated by various factors, including genetic factors, nutrition, hormone levels, blood pressure, impaired renal function, and duration of diabetes \[[@CR39], [@CR40]\]. Hcy is implicated in vascular diseases via endotoxic and pro-proliferative effects, which could interfere with glutathione synthesis and methylation reactions \[[@CR41]\]. Hcy promotes the occurrence and development of vascular diseases. Retinopathy was found to be prevalent in type 2 diabetes mellitus patients with higher Hcy concentrations. It may be a predictor of retinopathy in type 2 diabetes mellitus. However, whether plasma Hcy is involved in diabetic microvascular complications is not established \[[@CR27]\]. The association between Hcy and type 1 diabetes mellitus has gained increasing attention. In the early stages of type 1 diabetes mellitus, patients with proper renal function and hyperfiltration may have lower plasma Hcy levels. The present study showed that elevated Hcy level significantly increased the progression of diabetic retinopathy, especially in type 2 diabetes mellitus. However, this relationship was not statistically significant in type 1 diabetes mellitus.

Elevated Hcy level and low folic acid level was observed in diabetic patients, which was associated with high risk of proliferative retinopathy \[[@CR42]\]. The severity of diabetic retinopathy was found to be associated with lower folic acid and red blood cell folate levels \[[@CR43]\]. Long-term use of metformin increased the risk of vitamin B12 and folate deficiency, and thus influenced Hcy metabolism and contributed to the progression of diabetic retinopathy \[[@CR44]\]. A previous meta-analysis demonstrated hyperhomocysteinemia as a risk factor for the progression of diabetic retinopathy, especially for proliferative diabetic retinopathy. However, the results were based on continuous data, and a direct relationship was not confirmed \[[@CR8]\]. Further, factor-difference for the relationship between Hcy level and diabetic retinopathy was not calculated. Therefore, the current updated meta-analysis was conducted to explore the association between Hcy and the risk of diabetic retinopathy.

The present study had several limitations. First, this analysis did not include studies in languages other than English or when the corresponding author could not be contacted. Second, the summary risk for diabetic retinopathy was highly heterogeneous, and the source of heterogeneity could not be detected by a subgroup analysis. The heterogeneity may be due to the differences in geographical regions (nine countries and regions in 11 studies), study designs and methods, and methodological qualities. Third, the adjusted models were different across the included studies, and these factors might play an important role in the development of diabetic retinopathy. Finally, subgroup analysis based on patients with no proliferative or proliferative diabetic retinopathy was not conducted due to these data were available in few studies.

Conclusions {#Sec8}
===========

The present study demonstrated a strong positive correlation between plasma Hcy level and the progression of diabetic retinopathy. These data may help diabetic patients to achieve effective management in order to prevent the development and progression of diabetic retinopathy. Given the limitations of this study, further studies should be performed to confirm the findings and verify the effect of folic acid supplementation on the progression of diabetic retinopathy in diabetic patients.
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===============

 {#Sec9}

**Additional file 1.** Meta-regression.
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